Accel Wealth Management Recursion Pharmaceuticals, Inc. Transaction History
Accel Wealth Management
- $290 Million
- Q2 2025
A detailed history of Accel Wealth Management transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Accel Wealth Management holds 44,200 shares of RXRX stock, worth $286,858. This represents 0.08% of its overall portfolio holdings.
Number of Shares
44,200
Previous 44,050
0.34%
Holding current value
$286,858
Previous $255,000
12.55%
% of portfolio
0.08%
Previous 0.1%
Shares
5 transactions
Others Institutions Holding RXRX
# of Institutions
358Shares Held
285MCall Options Held
3.28MPut Options Held
3.16M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl34.8MShares$226 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.3MShares$210 Million0.0% of portfolio
-
Baillie Gifford & CO24.4MShares$158 Million0.12% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$112 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$95.2 Million0.27% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.17B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...